Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
17 03 2022
17 03 2022
Historique:
received:
12
11
2021
accepted:
28
12
2021
pubmed:
8
1
2022
medline:
5
4
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refine risk assessment across different conditioning intensities, we analyzed 810 adults transplanted in first or second remission after myeloablative conditioning (MAC; n = 515) or non-MAC (n = 295) who underwent multiparameter flow cytometry-based MRD testing before as well as 20 to 40 days after allografting. Patients without pre- and post-HCT MRD (MRDneg/MRDneg) had the lowest risks of relapse and highest relapse-free survival (RFS) and overall survival (OS). Relative to those patients, outcomes for MRDpos/MRDpos and MRDneg/MRDpos patients were poor regardless of conditioning intensity. Outcomes for MRDpos/MRDneg patients were intermediate. Among 161 patients with MRD before HCT, MRD was cleared more commonly with a MAC (85 of 104; 81.7%) than non-MAC (33 of 57; 57.9%) regimen (P = .002). Although non-MAC regimens were less likely to clear MRD, if they did, the impact on outcome was greater. Thus, there was a significant interaction between conditioning intensity and "MRD conversion" for relapse (P = .020), RFS (P = .002), and OS (P = .001). Similar findings were obtained in the subset of 590 patients receiving HLA-matched allografts. C-statistic values were higher (indicating higher predictive accuracy) for peri-HCT MRD dynamics compared with the isolated use of pre-HCT MRD status or post-HCT MRD status for prediction of relapse, RFS, and OS. Across conditioning intensities, peri-HCT MRD dynamics improve risk assessment over isolated pre- or post-HCT MRD assessments in patients with AML.
Identifiants
pubmed: 34995355
pii: S0006-4971(22)00035-0
doi: 10.1182/blood.2021014804
pmc: PMC8931514
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1694-1706Subventions
Organisme : NCI NIH HHS
ID : P01 CA018029
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA078902
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
© 2022 by The American Society of Hematology.
Références
Leukemia. 2017 Jul;31(7):1482-1490
pubmed: 28386105
Blood. 2021 Dec 30;138(26):2753-2767
pubmed: 34724563
Leukemia. 2021 Jun;35(6):1529-1538
pubmed: 33758317
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Curr Protoc Cytom. 2020 Jun;93(1):e73
pubmed: 32311834
Leukemia. 2015 Jan;29(1):137-44
pubmed: 24888275
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Leukemia. 2020 Jun;34(6):1577-1587
pubmed: 31974434
Leukemia. 2020 Jun;34(6):1701-1705
pubmed: 31796913
JAMA Oncol. 2020 Dec 1;6(12):1890-1899
pubmed: 33030517
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221
Blood. 2013 Sep 5;122(10):1813-21
pubmed: 23847197
Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8
pubmed: 25278455
Haematologica. 2017 May;102(5):865-873
pubmed: 28126965
Cancers (Basel). 2020 Aug 19;12(9):
pubmed: 32825022
J Clin Oncol. 2021 Mar 1;39(7):768-778
pubmed: 33373276
Leukemia. 2016 Jul;30(7):1456-64
pubmed: 27012865
J Clin Oncol. 2011 Mar 20;29(9):1190-7
pubmed: 21282535
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Bone Marrow Transplant. 2020 Mar;55(3):669-672
pubmed: 31685932
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2016 Feb 1;34(4):329-36
pubmed: 26668349